Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized ...
Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized ...
Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its Phase Ib/II study of ...
Though he is young to be diagnosed with the type of cancer, vigilance and understanding the risks have changed the course of ...
It's not too late to reshape and optimize your portfolio for what could be a very different market environment than last year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback